Clinical Research Directory
Browse clinical research sites, groups, and studies.
Single-ascending Dose Study of Kylo-12 in Healthy Subjects
Sponsor: Kylonova (Xiamen) Biopharma co., LTD.
Summary
This is a first-in-human, randomized, double-blind, placebo-controlled, single ascending dose study in healthy volunteers. Kylo-12 will be evaluated in approximately 50 subjects to assess safety, tolerability, pharmacokinetics and pharmacodynamic effects.
Official title: A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of Kylo-12 in Healthy Subjects
Key Details
Gender
All
Age Range
18 Years - 55 Years
Study Type
INTERVENTIONAL
Enrollment
50
Start Date
2025-03-12
Completion Date
2026-08-30
Last Updated
2026-03-16
Healthy Volunteers
Yes
Conditions
Interventions
Kylo-12
Administered SC.
Placebo
Administered SC.
Locations (1)
Chengdu Xinhua Hospital
Chengdu, Sichuan, China